A major international study, PORTEC-4a, provides the strongest evidence yet that molecular profiling can safely reduce radiotherapy for women with early stage endometrial cancer while identifying those who would benefit from more intensive treatment. The results, that will be presented at ESTRO 2025, the annual congress of the European Society for Radiotherapy and Oncology (ESTRO), mark a significant step forward in personalised cancer treatment.

Fiive pivotal studies presented at ESTRO 2025, the annual congress of the European Society for Radiotherapy and Oncology, showcase how radiotherapy is reshaping anal and rectan cancers treatment approaches. From reduced-dose treatments to cutting-edge combinations with immunotherapy and chemotherapy, these innovations offer safer, more effective, and organ-preserving alternatives to traditional surgery.

 

Retrospective study examines changes in early-stage stomach cancer detection over the past two decades, as stomach cancer remains one of the deadliest cancers globally.

Rates of anal cancer continue to steadily increase in the U.S. with the largest jump among older women. 

The phase III study shows that giving prostate cancer patients fewer, higher doses of radiotherapy can be safe and effective in the long term.

Despite decades of public health messaging, Canadians are spending more time in the sun and using less sun protection – raising alarms among researchers as melanoma cases continue to climb.

That trend is highlighted in a McGill University-led study that analyzed national survey data collected between 2011 and 2018 from over 77,000 people, representing a weighted sample of 21 million Canadians.

NRG Oncology (NRG), a National Cancer Institute (NCI) National Clinical Trials Network (NCTN) group focused on improving outcomes for adults with cancer through multi-center clinical research, recently announced it added two new Chairs to the organization’s Lung Cancer Committee and Imaging Committee.

A new first-in-human study at Dartmouth Cancer Center evaluated ABY-029, a fluorescent molecule designed to highlight soft-tissue sarcomas during surgery. Given to patients before surgery, the molecule proved safe and showed a strong correlation between its glow and tumor presence. This innovation aims to improve surgical precision by making cancer cells visible, potentially leading to more complete tumor removal, higher cure rates, and minimized injury to healthy tissues.

Researchers at the University of Minnesota have completed a first-in-human clinical trial testing a CRISPR/Cas9 gene-editing technique to help the immune system fight advanced gastrointestinal (GI) cancers. The results, recently published in Lancet Oncology, show encouraging signs of safety and potential effectiveness of the treatment.